Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 1.00 |
| ▸ | CA4 | P22748 | 1/20 | 1.00 |
| ▸ | ENO1 | P06733 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | OTC | P00480 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sparfosic Acid SCHEMBL3514530 | 1.00 | CA2 (1.00) | CA2CA4ENO1MEN1LMNA | |
| Sparfosic Acid SCHEMBL31237824 | 0.98 | CA2 (0.96) | CA2CA4ENO1MEN1LMNA | |
| Pala SCHEMBL11121904 | 0.98 | CA2 (0.96) | CA2CA4ENO1MEN1LMNA | |
| Pala SCHEMBL31389020 | 0.98 | CA2 (0.96) | CA2CA4ENO1MEN1LMNA | |
| Pala SCHEMBL859680 | 0.98 | CA2 (0.96) | CA2CA4ENO1MEN1LMNA | |
| SCHEMBL7747522 | 0.85 | CA2 (0.74) | CA2CA4ENO1MEN1KMT2A | |
| Pala SCHEMBL3514468 | 0.85 | CA2 (0.72) | CA2CA4FOLH1OTC | |
| SCHEMBL3513056 | 0.84 | CA2 (0.71) | CA2CA4HPGDFOLH1GGH | |
| SCHEMBL12990268 | 0.84 | CA2 (0.71) | CA2CA4HPGDFOLH1GGH | |
| Sparfosic Acid SCHEMBL28558641 | 0.84 | CA2 (0.72) | CA2CA4ENO1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5397 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4687871-A1 | TOPICAL PALA THERAPY FOR CANCER | The Cleveland Clinic Foundation (US) | 2026-02-11 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20250268993-A1 | ALKALINE PHOSPHATE-BASED ONCOLOGY TREATMENTS | THERIVA BIOLOGICS, INC. | 2025-08-28 | — | — | US | claimed |
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| US-12318434-B2 | Alkaline phosphate-based oncology treatments | THERIVA BIOLOGICS, INC. (US) | 2025-06-03 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| WO-2024206402-A1 | TOPICAL PALA THERAPY FOR CANCER | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-10-03 | — | — | WO | claimed |
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| US-20220333137-A1 | METHODS AND PRODUCTS FOR PRODUCING ENGINEERED MAMMALIAN CELL LINES WITH AMPLIFIED TRANSGENES | PRECISION BIOSCIENCES, INC. (US) | 2022-10-20 | — | — | US | claimed |
| EP-0160079-A4 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION. | GREER SHELDON B | 1986-05-14 | — | — | EP | claimed |
| EP-0160079-A1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION. | GREER SHELDON B | 1985-11-06 | — | — | EP | claimed |
| WO-1985001871-A1 | METHOD AND MATERIALS FOR SENSITIZING NEOPLASTIC TISSUE TO RADIATION | GREER SHELDON B | 1985-05-09 | — | — | WO | claimed |
| US-4442203-A | OR ABNORMAL GENETIC LABILITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1984-04-10 | — | — | US | claimed |
| US-4348522-A | ANTITUMOR | STARKS ASSOCIATES, INC. (US) | 1982-09-07 | — | — | US | claimed |
| US-4267126-A | ANTITUMOR AGENTS | STARKS ASSOCIATES, INC. (US) | 1981-05-12 | — | — | US | claimed |
| US-4215070-A | DISODIUM SALT AS ANTITUMOR AGENT | STARKS ASSOCIATES, INC. (US) | 1980-07-29 | — | — | US | claimed |
| US-4179464-A | Preparation of N-(phosphonoacetyl)-L-aspartic acid | SCHULTZ ROBERT J | 1979-12-18 | — | — | US | claimed |
| US-4178306-A | Preparation of N-(phosphonoacetyl)-L-aspartic acid | PARSONS JACK L | 1979-12-11 | — | — | US | claimed |
| US-4154759-A | Preparation of N-(phosphonoacetyl)-L-aspartic acid | DUBICKI HENRYK | 1979-05-15 | — | — | US | claimed |